1. Home
  2. PRAX vs TGB Comparison

PRAX vs TGB Comparison

Compare PRAX & TGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRAX
  • TGB
  • Stock Information
  • Founded
  • PRAX 2015
  • TGB 1966
  • Country
  • PRAX United States
  • TGB Canada
  • Employees
  • PRAX N/A
  • TGB N/A
  • Industry
  • PRAX Biotechnology: Pharmaceutical Preparations
  • TGB Precious Metals
  • Sector
  • PRAX Health Care
  • TGB Basic Materials
  • Exchange
  • PRAX Nasdaq
  • TGB Nasdaq
  • Market Cap
  • PRAX 599.7M
  • TGB 698.1M
  • IPO Year
  • PRAX 2020
  • TGB N/A
  • Fundamental
  • Price
  • PRAX $46.32
  • TGB $3.37
  • Analyst Decision
  • PRAX Strong Buy
  • TGB
  • Analyst Count
  • PRAX 11
  • TGB 0
  • Target Price
  • PRAX $114.73
  • TGB N/A
  • AVG Volume (30 Days)
  • PRAX 299.7K
  • TGB 14.5M
  • Earning Date
  • PRAX 08-12-2025
  • TGB 07-30-2025
  • Dividend Yield
  • PRAX N/A
  • TGB N/A
  • EPS Growth
  • PRAX N/A
  • TGB N/A
  • EPS
  • PRAX N/A
  • TGB N/A
  • Revenue
  • PRAX $8,122,000.00
  • TGB $417,640,101.00
  • Revenue This Year
  • PRAX N/A
  • TGB $22.13
  • Revenue Next Year
  • PRAX $6,358.50
  • TGB $36.13
  • P/E Ratio
  • PRAX N/A
  • TGB N/A
  • Revenue Growth
  • PRAX 270.02
  • TGB 7.89
  • 52 Week Low
  • PRAX $26.70
  • TGB $1.67
  • 52 Week High
  • PRAX $91.83
  • TGB $3.39
  • Technical
  • Relative Strength Index (RSI)
  • PRAX 63.87
  • TGB 71.81
  • Support Level
  • PRAX $40.93
  • TGB $3.03
  • Resistance Level
  • PRAX $44.40
  • TGB $3.02
  • Average True Range (ATR)
  • PRAX 2.26
  • TGB 0.14
  • MACD
  • PRAX -0.08
  • TGB 0.02
  • Stochastic Oscillator
  • PRAX 95.12
  • TGB 96.77

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

About TGB Taseko Mines Ltd.

Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.

Share on Social Networks: